< Return to Class Actions List

McPhadden Samac Tuovi has commenced a proposed Class Action against Pfizer, Inc. and Pfizer Canada Limited relative to the smoking cessation drug Champix (varenicline).

The legal proceeding involves people who took Champix and allege that they developed psychological side effects that may have included attempted suicide. It is alleged that Pfizer failed to warn the public about the potential of these adverse side effects.

Champix is a smoking cessation drug that was introduced for distribution and sale in the Canadian market in or about April 2007. It is known commercially as “Chantix” in the United States.

In the first eight months following its introduction onto the Canadian market, Health Canada’s Adverse Drug Reaction Monitoring Program reported 107 cases of adverse neuropsychotic reactions. Accordingly, the Canadian product monograph was revised to indicate post-market reports of depressed mood, agitation, changes in behaviour, suicidal ideation and suicide.

On June 16, 2008, Health Canada noted that by April 30 2008, a total of 226 cases of neuropsychotic adverse events had been reported involving the use of Champix.

If you would like further information about this proposed Class Action, please contact us directly. All inquiries will be kept confidential.  

Champix® is a registered trademark of Pfizer, Inc. and is used here only to identify the product in question.

< Return to Class Actions List